Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
TRDA Entrada Therapeutics
15.710+0.260+1.68%
Close
02/07 16:00 ET
15.7100.0000.00%
Post Mkt Price 02/07 16:00 ET
High
15.910
Open
15.290
Turnover
613.47K
Low
15.200
Pre Close
15.450
Volume
39.52K
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Entrada Therapeutics Announces Clinical Candidate ENTR-601-45
Entrada Therapeutics Announces Clinical Candidate, ENTR-601-45, for the Potential Treatment of People Living With Duchenne Muscular Dystrophy Who Are Exon 45 Skipping Amenable
BOSTON, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Entrada Therapeutics, Inc. - TRDA
New York, New York--(Newsfile Corp. - January 7, 2023) - Pomerantz LLP is investigating claims on behalf of investors of Entrada Therapeutics, Inc. ("Entrada" or the "Company") (NASDAQ: TRDA). Such
Insider Selling: Entrada Therapeutics, Inc. (NASDAQ:TRDA) CEO Sells $145,228.38 in Stock
Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Rating) CEO Dipal Doshi sold 9,669 shares of the firm's stock in a transaction that occurred on Tuesday, December 27th. The shares were sold at an averag
Dipal Doshi Sells 9,669 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stock
Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Rating) CEO Dipal Doshi sold 9,669 shares of the business's stock in a transaction on Tuesday, December 27th. The shares were sold at an average price of
Insider Sell: Entrada Therapeutics
04:58 PM EST, 12/29/2022 (MT Newswires) -- Dipal Doshi, Director, President and CEO, on December 27, 2022, sold 14,590 shares in Entrada Therapeutics (TRDA) for $219,119. Following the Form 4 filing w
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA
NEW YORK, Dec. 26, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Entrada Therapeutics, Inc. ("Entrada" or the "Company") (NASDAQ: TRDA). Such investors are ad
Bronstein, Gewirtz & Grossman, LLC Announces Entrada Therapeutics, Inc. (TRDA) Investigation
Sector Update: Healthcare Stocks Fade in Late Trading
03:44 PM EST, 12/20/2022 (MT Newswires) -- Healthcare stocks were little changed Tuesday afternoon, with the NYSE Health Care Index and the SPDR Health Care Select Sector ETF (XLV) both rising less th
Why IceCure Medical Shares Are Trading Higher By 296%? Here Are 64 Stocks Moving In Tuesday's Mid-Day Session
Gainers IceCure Medical Ltd (NASDAQ:ICCM) shares jumped 296% to $3.71 after the company announced interim results from the ICESECRET study for the treatment of patients with small renal masses who can
Company Overview
More
Entrada Therapeutics, Inc. operates as a biotechnology company. It focuses on delivery of biomolecules into the cell to treat devastating diseases. The firm offers intracellular enzyme replacement therapy and protein-protein interaction inhibitors programs. The company focuses on creating and expanding pipeline of oligonucleotide, antibody, enzyme, protein and peptide programs to target and engage underlying drivers of diseases. Entrada Therapeutics was founded by Dehua Pei in September 22, 2016 and is headquartered in Boston, MA.
CEO： Mr. Dipal Doshi
Market： NASDAQ
Listing Date： 10/29/2021
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet